Author Archives: Julian Upton

Innovation Drops Down NICE’s Value Agenda

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
Posted in Europe, Events, pricing | Tagged , , , , , | Leave a comment

Bioscience Research: China to Overtake U.S. by 2020

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
Posted in Biotech, Emerging Markets, Gene therapy, Global, R&D | Tagged , , , , | Leave a comment

Pharma Seizes Latin American Opportunities

Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years. And with untapped potential identified in countries across the region, companies are expected to seize upon further opportunities to drive future growth, says a new report from GlobalData.
Posted in Emerging Markets, Market Access | Tagged , , , , , , | Leave a comment

NICE's Tarceva Decision "Perverse", Says Roche

The UK National Institute for Health and Care Excellence’s (NICE) decision that relapsed non-small cell lung cancer patients should no longer have access to Roche’s cancer pill Tarceva (erlotinib) is a setback for lung cancer care in England and Wales, where “over 1,000 patients a year will be left without an active treatment option after […]
Posted in pricing, Regulatory | Tagged , , , , , | Leave a comment

BRIC Opportunities 2014

While the tide has been turning for pharma in the BRIC markets, they will continue to be important but only if the industry has learnt the hard lessons of the last few years. Speaking to Pharm Exec for the 2014 Industry Outlook, Reenita Das, Partner at Frost & Sullivan, says its now more important than […]
Posted in Global, Strategy | Tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta